Floatz logo

Relatlimab

Advanced Cancer

Bristol-Myers Squibbmonoclonal_antibodyPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
73/ 100

Competitive context

1411 Active assets in the Advanced Cancer cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB
Vitamin B6
M.D. Anderson Cancer Center
Phase 4BB
Inno-206
M.D. Anderson Cancer Center
Phase 2BB
Rivoceranib
Jiangsu HengRui Medicine Co., Ltd.
Phase 4BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB

View all 50 →

Same molecule, other indications

Relatlimab is also rated in:

neoplasmDormant
BB
Indicative ·
68 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
66 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →